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CA125 levels in overnight effluent were significantly higher
with bicPDF (61.9 ± 33.2 U/L) than with SPDF (18.6 ±
18.2 U/L, p < 0.001). Hyaluronic acid levels were signifi-
cantly lower after the use of bicPDF (185.0 ± 119.6 ng/mL)
than after SPDF (257.4 ± 174.0 ng/mL, p = 0.013). Both
TNF-
aa
aa
a  and TGF-
bb
bb
b 1 showed higher levels with the use of
bicPDF than with SPDF. No differences were observed for
IL-6, VEGF, or IFN
gg
gg
g  levels. We observed an improvement in
the glomerular filtration rate with the use of bicPDF but no
differences were observed for total fluid loss. Pain scores
could be analyzed in 23 patients: there was no difference
between the solutions.
¤¤
¤¤
¤ Conclusions: The use of a purely bicarbonate-buffered
low-glucose degradation product solution significantly
changes most of the peritoneal effluent markers measured,
suggesting an improvement in peritoneal membrane integ-
rity. Additionally, it seems to have a positive effect on re-
sidual renal function.
Perit Dial Int 2009; 29:647–655 www.PDIConnect.com
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In peritoneal dialysis (PD), the rationale of bicarbon-ate as buffer substance in the dialysis fluid is evident
but requires technological measures to overcome the for-
mation of calcium and magnesium carbonate precipita-
tion (1). This precipitation is avoided by preparing the
solution in a double-chamber bag, allowing the use of
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¤¤
¤¤
¤ Background: Novel peritoneal dialysis solutions are char-
acterized by a minimal content of glucose degradation prod-
ucts and a neutral pH. Many studies have shown the
biocompatibility of neutral lactate-buffered solutions; how-
ever, until now, the effect of purely bicarbonate-buffered
solutions has not been intensively studied in vivo.
¤¤
¤¤
¤ Methods: This study was an open label, prospective, cross-
over multicenter trial to investigate the biocompatibility of
a purely bicarbonate-buffered solution (bicPDF) by measur-
ing biocompatibility parameters such as cancer antigen 125
(CA125) in peritoneal effluent. 55 patients were enrolled in
the study. After a 2-week run-in phase, 53 patients could be
randomized into 2 groups, starting with either standard lac-
tate-buffered peritoneal dialysis fluid (SPDF) for 12 weeks
(phase 1) and then switching to bicPDF for 12 weeks
(phase 2), or vice versa. Overnight peritoneal effluents were
collected at baseline and at the end of phases 1 and 2 and
were tested for CA125, hyaluronic acid, vascular endothe-
lial growth factor (VEGF), tumor necrosis factor-alpha
(TNF-
aa
aa
a ), interleukin 6 (IL-6), interferon gamma (IFN
gg
gg
g ),
and transforming growth factor-beta1 (TGF- bb bb b 1). Total ul-
trafiltration and residual renal function were also assessed.
At the end of the study, pain during fluid exchange and dwell
was evaluated using special questionnaires.
¤¤
¤¤
¤ Results: 34 patients completed the study; 27 of them pro-
vided data for analysis of the biocompatibility parameters.
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stratifying for diabetes status and time on PD
(£ 18 months and >18 months on PD). Stable patients on
the stay·safe CAPD system (Fresenius Medical Care, Bad
Homburg, Germany) with no PD-related complications
during the previous month were asked to sign informed
consent. Approval for the study was obtained from the
local ethics committees in each country.
All patients underwent an initial 2-week run-in phase
with standard lactate-buffered peritoneal dialysis fluid
(SPDF) with the appropriate glucose concentration
(1.5%, 2.3%, or 4.25%). Afterward, the patients were
randomly assigned to two groups, starting with either
SPDF for 12 weeks (phase 1) and switching to bicPDF for
another 12 weeks (phase 2), or vice versa (Figure 1). All
study solutions were manufactured by Fresenius Medi-
cal Care, Bad Homburg, Germany, and had compositions
as shown in Table 1.
After completing this biocompatibility study phase,
pain assessment was performed during a so-called pain
assessment phase (Figure 1) to allow blinded adminis-
tration of the solutions.
BIOCOMPATIBILITY MARKERS IN EFFLUENT AND SERUM
Effluent samples from overnight dwells of 9 – 12 hours
were collected for analysis of biocompatibility markers
at the end of the run-in phase (baseline) and at the end
of each treatment phase (visits 2, 3, and 4). For the over-
night exchanges, the patients used 2-L bags with 2.3%
glucose. Dialysate sampling from the effluent was per-
formed through a 0.2-m  filter. Samples were stored im-
mediately at –20°C until analysis at a central laboratory
(Department of Clinical Research, Medilab Kliniska
Laboratorier AB, Täby, Sweden).
Cancer antigen 125 was measured with the Liaison
chemiluminescence assay (DiaSorin SpA, Saluggia,
Italy). Hyaluronic acid (HA) was determined with a sand-
wich protein-binding assay in microplate format
(Corgenix Ltd., Peterborough, UK). Tumor necrosis fac-
tor-alpha (TNF-a ) and interleukin-6 (IL-6) were analyzed
with the Quantikine high-sensitivity ELISA (R&D Sys-
tems, Minneapolis, MN, USA). Vascular endothelial
growth factor (VEGF), interferon gamma (IFN g ), and
transforming growth factor-beta1 (TGF- b 1) were mea-
sured with the quantitative sandwich enzyme immunoas-
say technique (R&D Systems). High-sensitivity C-reactive
protein was analyzed with a near-infrared particle im-
munoassay rate methodology (Synchron LX Systems;
Beckman Coulter, Brea, CA, USA). Interleukin-6 was also
analyzed in serum using the same method as used for
dialysate samples. All these analyses were performed
following the manufacturers’ instructions.
pure bicarbonate as buffer substance. Further, the sepa-
ration of glucose in one chamber and its sterilization at
acidic pH minimizes the formation of glucose degrada-
tion products (GDPs). Mixing the compartments together
before use results in a solution at physiological pH (ap-
proximately 7.4) with low GDP content (2).
High concentrations of glucose and especially GDPs in
conventional PD fluids (PDFs) leads to the formation of
advanced glycation end products (AGEs) in the peritoneal
membrane (3). Accumulation of AGE in the peritoneum
correlates with the development of severe interstitial
fibrosis and microvascular sclerosis (4,5). Superior bio-
compatibility of purely bicarbonate-buffered PDFs com-
pared to conventional PDFs has been demonstrated in
several in vitro studies (6–9) and studies in children (10).
The low pH of PDFs and high pCO2 were suggested as
pivotal causes of infusion pain (11,12). Henderson et al.
(13) found that the intensity of abdominal pain experi-
enced by some patients on continuous ambulatory peri-
toneal dialysis (CAPD) during infusion of PDF correlates
with the storage time of the solutions prior to use. Spec-
trophotometric analysis of these PDFs revealed a signifi-
cant presence of GDP in aged solutions. Fewer local
effects, including infusion pain during solution exchange,
have been observed with the use of biocompatible solu-
tions (e.g., purely bicarbonate-buffered solutions) (14).
Bicarbonate-buffered solutions (34 mmol/L) have
also been shown to be more effective than conventional
lactate-buffered solution (35 mmol/L) in the correction
of acidosis (14). Due to their low GDP content and physi-
ological pH, the use of purely bicarbonate-buffered so-
lutions permits a more physiological treatment. This
study addresses whether this results in beneficial effects,
such as better preservation of the peritoneal membrane
and potential clinical effects.
The primary aim of the present study was to investi-
gate the in vivo biocompatibility of a 34 mmol/L bicarbon-
ate-buffered PDF (bicPDF) in adults. Peritoneal membrane
integrity was assessed by several markers, including can-
cer antigen 125 (CA125), which has been identified to
correlate with mesothelial cell mass and turnover (15).
As secondary objectives, the effect of a bicarbonate-
buffered PDF on residual renal function (RRF) and its
value for pain relief were investigated.
SUBJECTS AND METHODS
STUDY DESIGN
This was an open label, prospective, crossover multi-
center trial with two treatment periods in random order.
A centralized randomization procedure was applied
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RESIDUAL RENAL FUNCTION AND TOTAL FLUID LOSS
Residual renal function and total fluid loss were as-
sessed during visits 2, 3, and 4. For this purpose, the
patients performed a 24-hour dialysate and urine col-
lection, in which both urea and creatinine concentrations
were measured. Glomerular filtration rate (GFR) was cal-
culated using the formula GFR = (renal creatinine clear-
ance + renal urea clearance) × 0.5.
Total fluid loss was estimated as the sum of urine vol-
ume and net ultrafiltration (UF) volume. For the assess-
ment of net UF, the patients weighed the bags before
and after each dwell during the day preceding the study
visit. The UF of each dwell was calculated as the differ-
ence between outflow volume and inflow volume. Net UF
volume was then calculated as the sum of the UF of each
dwell.
PERITONEAL FUNCTION AND ACID–BASE PARAMETERS
Peritoneal function and acid–base parameters were
measured during visits 2, 3, and 4. Peritoneal function
was assessed using the peritoneal equilibration test ac-
cording to Twardowski et al. (16).
Acid–base parameters were analyzed by standard
methods applied at each study site.
PAIN ASSESSMENT PHASE
The aim of this phase was to assess pain levels during
the exchange and the dwell of the PD solutions. To en-
able a blinded application to the patients, this phase was
added at the end of the otherwise open study. For this
purpose, the patients underwent four exchanges at the
study center: two with SPDF and two with bicPDF. These
exchanges were standardized to 2-L 4.25% glucose bags
for a 3-hour dwell time. The order in which the patient
received the solutions was centrally randomized and in-
dependent of the visit. The exchanges were performed
Figure 1 — Diagram of study design. SPDF = standard lactate-buffered peritoneal dialysis fluid; bicPDF = purely bicarbonate-
buffered peritoneal dialysis fluid.
TABLE 1
Composition of Study Solutions
SPDF bicPDF
Sodium (mmol/L) 134 134
Calcium (mmol/L) 1.75 1.75
Magnesium (mmol/L) 0.5 0.5
Chloride (mmol/L) 103.5 104.5
L-Lactate (mmol/L) 35 —
Bicarbonate (mmol/L) — 34
Glucose (g/L) 15.0/42.5/22.7 15.0/42.5/22.7
Osmolaritya (mOsm/L) 358/511/401 358/509/399
pH approx. 5.5 approx. 7.4
SPDF = standard lactate-buffered peritoneal dialysis fluid;
bicPDF = purely bicarbonate-buffered peritoneal dialysis fluid.
a Theoretical.
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by the nurse and the bags were blinded; thus, the solu-
tion type was unknown to the patients. According to pa-
tient preference, these four exchanges were performed
either at four different visits or during two visits with
two exchanges each.
During these exchanges, the McGill Pain Question-
naire (12,17) and an additional specific questionnaire
designed to assess pain at different time points during
inflow, dwell, and outflow were applied. The question-
naires comprised a scoring system and had to be read
out to the patient at the clinic.
STATISTICAL METHODS
For the inductive analysis of biocompatibility mark-
ers, GFR, and total fluid loss (UF + 24 urine volume), lin-
ear mixed models were used and included solution type
(bicPDF/SPDF), time (visit 3/visit 4), and the respective
baseline values as fixed effects. The individual patient
was also implemented as a random effect into these
models. For other parameters, descriptive analyses with
95% confidence intervals for the intraindividual mean
differences between the solution types were calculated.
If not stated otherwise, results are given as mean ± stan-
dard deviation. The complete analysis was performed
with the statistical software SAS 9.1.3 (SAS Institute,
Cary, NC, USA).
RESULTS
STUDY POPULATION
This study was performed in 13 centers in Sweden,
2 in The Netherlands, and 1 in Switzerland. A total of
55 CAPD patients were recruited (1 center recruited
6 patients, 5 centers recruited 5 patients each, 3 cen-
ters recruited 4 patients each, 1 center recruited 3 pa-
tients, 3 centers recruited 2 patients each, and 3 centers
recruited 1 patient each).
During the run-in phase, 2 patients dropped out of
the study (due to patient wish and an adverse event not
related to the PD solution); therefore, 53 patients were
randomized and started the study phase (Table 2). Of
these 53, 19 discontinued the treatment prematurely.
Reasons for dropout during the treatment with SPDF
were transplantation (n = 3), patient wish (n = 2), peri-
tonitis (n = 1), adverse events not related to the PD so-
lution (n = 3), and death (n = 2). Patients dropped out
during the treatment with bicPDF due to patient wish
(n = 4) and adverse events not related to the PD solu-
tion (n = 4). Therefore, 34 patients finished the study.
In the full analysis set, 27 patients without major pro-
tocol violations were included (representing the pa-
tients completing the study per protocol). Seven pa-
tients could not be included in this analysis set due to
missing data for CA125 (n = 3), randomization failure
(n = 1), overnight dwell <9 hours (n = 1), and implau-
sible data (n = 2). In this population, biocompatibility
parameters as primary target variables, RRF, total fluid
loss, and biochemical parameters were assessed.
Twenty-three patients that performed the pain assess-
ment phase and that had complete questionnaires for
assessing pain were included in the pain assessment
analysis set. The baseline characteristics of all random-
ized patients and both analysis populations are pre-
sented in Table 2.
BIOCOMPATIBILITY MARKERS IN EFFLUENT AND SERUM
The levels of CA125 measured in the overnight efflu-
ents. At baseline it was 17.4 ± 13.5 U/L. CA125 was sig-
nificantly higher at the end of the 12-week period with
bicPDF (61.9 ± 33.2 U/L) than after the period with SPDF
(18.6 ± 18.2 U/L, p < 0.001) (Figure 2). Hyaluronic acid
level in overnight effluent  was 244.2 ± 167.7 ng/mL at
baseline. At the end of the 12-week periods it was sig-
nificantly lower after bicPDF (185.0 ± 119.6 ng/mL)
than after SPDF (257.4 ± 174.0 ng/mL, p = 0.013) (Fig-
ure 2).
Both TNF-a  and TGF-b 1 levels were higher with bicPDF
than with SPDF. No significant differences could be dem-
onstrated in overnight effluent levels of IL-6, VEGF, or
IFNg  with either bicPDF or SPDF. Serum IL-6 and C-reac-
tive protein levels also did not show significant differ-
ences (Table 3).
RESIDUAL RENAL FUNCTION AND TOTAL FLUID LOSS
At baseline, GFR was 4.48 ± 3.20 mL/minute, daily
urine volume was 1090 ± 724 mL, and 24-hour UF was
640 ± 102 mL.
We determined a GFR of 4.33 ± 3.42 mL/minute with
SPDF and 4.82 ± 3.32 mL/minute (p = 0.011) with bicPDF
(Figure 3). The daily urine volume was 1398 ± 975 mL at
the end of the bicPDF phase, which was significantly
higher that at the end of the SPDF phase (1071 ± 753 mL,
p < 0.001). At the same time, 24-hour UF tended to be
lower after 12 weeks’ treatment with bicPDF (494 ±
771 mL) than with SPDF (727 ± 938 mL, p = NS). No dif-
ferences in the average glucose strength of the PD solu-
tions between the two phases were observed. The
difference in total fluid loss between the two solutions
was not significant (Figure 3). No changes in body weight
were observed.
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TABLE 2
Baseline Patient Characteristics for All Patients Randomized, the Full Analysis Set (FAS), and the
Pain Assessment Analysis Set (PAS) (Values Reported as Mean±SD, as Appropriate)
All patients randomized FAS PAS
N 53 27 23
Sex (M:F) 31:22 16:11 15:8
Age (years) 60.9±14.8 56.0±16.8 58.7±16.4
Height (cm) 170.9±9.1 170.3±10.1 170.3±9.2
Weight (kg) 75.3±14.9 73.9±16.8 73.3±16.2
Body mass index (kg/m2) 25.7±3.9 25.3±4.0 25.1±4.1
Time on peritoneal dialysis (months) 10.9±10.8 7.0±5.4 9.0±9.2
Primary renal disease (n)
Diabetic nephropathy 16 7 4
Glomerulonephritis 11 6 8
Hypertensive nephropathy 9 3 3
Other vascular disease 3 2 1
Polycystic kidney disease 5 4 3
Other 6 3 2
Unknown 3 2 2
TABLE 3
Biocompatibility Markers in Dialysate and Serum (Values Reported as Mean±SD)
Baseline SPDF bicPDF p Valuea
IL-6 (pg/mL) 23.0±17.6 21.7±19.1 25.5±36.9 NS
TNF-a  (pg/mL) 0.8±0.3 0.6±0.3 1.0±0.4 <0.001
VEGF (pg/mL) 47.3±14.8 40.1±19.0 44.3±16.8 NS
IFN g  (pg/mL) 1.8±2.4 2.1±3.3 1.5±2.9 NS
TGF-b 1 (pg/mL) 67.7±35.3 45.7±27.1 62.0±43.8 0.016
IL-6 in serum (pg/mL) 5.7±3.9 4.7±2.7 5.3±2.8 NS
CRP in serum (mg/L) 7.0±13.0 5.4±9.4 5.2±9.0 NS
IL = interleukin; TNF-a  = tumor necrosis factor-alpha; VEGF = vascular endothelial growth factor; IFN g  = interferon gamma; TGF-b 1 =
transforming growth factor-beta1; CRP = C-reactive protein; SPDF = standard lactate-buffered peritoneal dialysis fluid; bicPDF =
purely bicarbonate-buffered peritoneal dialysis fluid.
a p Values result from the linear mixed models analysis.
Figure 2 — Calcium antigen 125 (CA125; panel A) and hyaluronic acid (HA; panel B) levels at baseline, at the end of the 12 weeks of
treatment with the standard lactate-buffered peritoneal dialysis fluid (SPDF) and the purely bicarbonate-buffered peritoneal dialy-
sis fluid (bicPDF).
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PERITONEAL FUNCTION AND ACID–BASE PARAMETERS
No changes in dialysate-to-plasma ratios of creatinine
and urea were observed with the use of bicPDF and SPDF
(data not shown).
pH and base excess increased with the use of bicPDF
compared to SPDF; other acid–base variables were un-
changed (Table 4).
PAIN ASSESSMENT PHASE
On the visual analog scale for pain intensity in the
McGill Pain Questionnaire, a value of 0 represents no pain
and 10 the most pain possible. The patients marked a
pain intensity of 0.29 ± 0.52 for bicPDF and 0.54 ± 1.14
for SPDF (p = NS).
In the specific questionnaire on pain related to solu-
tion exchange, 4 of 23 patients reported mild or moder-
ate pain with both solutions during inflow. Two patients
reported pain during dwells with bicPDF and 3 patients
with SPDF. Two patients complained of mild or moder-
ate pain during outflow with bicPDF and 5 patients with
SPDF.
DISCUSSION
The present crossover study compared the in vivo bio-
compatibility of a purely bicarbonate-buffered PDF char-
acterized by physiological pH and low levels of GDPs
against a conventional lactate-buffered PDF. Compari-
son was made using effluent parameters considered bio-
compatibility markers of PD solutions, such as CA125
(15,18–20). The concentration of CA125 measured in the
overnight effluent was significantly elevated at the end
of the bicarbonate treatment phase compared to the con-
ventional PDF treatment phase.
Biocompatibility of lactate- and lactate/bicarbonate-
buffered PD solutions with reduced GDP levels and less-
acidic or neutral pH has already been demonstrated in
several studies (18–22). Williams et al. (20) observed
three- to fourfold increases in CA125 levels in overnight
effluent when using the biocompatible lactate-buffered
Figure 3 — Glomerular filtration rate (GFR; panel A) and 24-hour urine volume, peritoneal net ultrafiltration, and total fluid loss
(panel B) with the use of purely bicarbonate-buffered peritoneal dialysis fluid (bicPDF) and standard lactate-buffered peritoneal
dialysis fluid (SPDF).
TABLE 4
Acid–Base Parameters
Baseline SPDF bicPDF
N (mean±SD) N (mean±SD) N (mean±SD)
Bicarbonate (mmol/L) 25 24.0±3.3 27 24.6±3.8 27 25.4±3.0
Venous pH 27 7.3±0.01 24 7.3±0.1 24 7.4±0.1a
Base excess (mmol/L) 26 –0.7±3.1 24 –1.2±3.9 27 1.0±3.7a
pCO2 (kPa) 27 6.5±1.0 25 6.6±1.0 25 6.5±1.1
pO2 (kPa) 26 6.0±6.0 23 5.1±2.8 22 5.0±2.2
SPDF = standard lactate-buffered peritoneal dialysis fluid; bicPDF = purely bicarbonate-buffered peritoneal dialysis fluid.
a Significant according to 95% confidence interval of the intraindividual differences between SPDF and bic PDF.
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solution during 3 months. Although it is observed that,
with the duration of the PD treatment, CA125 levels de-
cline (21), elevated CA125 related to the use of bio-
compatible PDF has been observed also in other studies
(19,20,23–25) with up to 2 years of treatment (18).
Before the present in vivo study, the effects of purely
bicarbonate-buffered solutions on the peritoneal mem-
brane had been investigated only in children (10). The
increased CA125 levels in effluent collected during a
4-hour peritoneal equilibration test in children on au-
tomated PD (10) and the recently published first results
in adults (26) are now confirmed by our study in a larger
adult patient population. Increased CA125 levels are con-
sidered associated with a better preservation of the me-
sothelial cell layer, possibly by an increase in mesothelial
cell mass and function (27).
In the present study we observed a significant de-
crease in effluent HA concentrations when patients used
bicPDF, suggesting a lower proinflammatory potential of
this solution since HA is produced by mesothelial cells
and is considered a surrogate marker of peritoneal in-
flammation (28). Hyaluronic acid is increased during
peritonitis (29) and is involved in peritoneal remodel-
ing processes. Our results are in agreement with studies
using biocompatible lactate-buffered PD solutions that
are also characterized by neutral pH and low GDP con-
tent (18–20).
We also determined the concentrations of IL-6, IFNg ,
TNF-a , VEGF, and TGF-b 1 in overnight dialysate. Whereas
no significant differences were observed for IL-6, IFNg ,
or VEGF, both TNF-a  and TGF- b 1 showed a slight but sig-
nificant increase in the bicPDF phase. These results seem
to contradict the hypothesis of a lower proinflammatory
effect of biocompatible solutions, as suggested by the
reduced HA. However, increased secretion of these me-
diators could be interpreted as being a result of improved
peritoneal macrophage and mesothelial function with
the use of bicPDF, which is in line with data from ex vivo
and in vitro studies (30–32). As increase CA125 concen-
tration in the peritoneal effluent is considered an indi-
cator of an improved mesothelial cell mass, it might be
possible that increased secretion of TNF-a  and TGF- b 1 is
a consequence of increased mesothelial cell numbers and
improved mesothelial cell function. The relevance of
these findings should be interpreted with caution be-
cause all levels of TNF-a  and TGF-b 1 in our study were
far below the levels found in other studies (19,20,23)
and because the levels found with bicPDF were compa-
rable to those at baseline (Table 3). An alternative ex-
planation for the increased TNF-a  levels during bicPDF
might be an increased release of TNF-a  by macrophages
during peritonitis (33), but the incidence of peritonitis
was not different between the two solutions (data not
shown).
The purely bicarbonate-buffered PDF induced a sig-
nificant increase in RRF — measured as residual GFR and
diuresis. This improvement in RRF with bicPDF was ob-
served independently of the order in which SPDF and
bicPDF were applied, thereby excluding natural decline
of renal function as a confounding factor. It is possible
that the bicPDF has a positive influence on RRF as such
by reducing potential AGE-related systemic damage to
the kidney (34). Parallel to the increase in RRF, we ob-
served a slightly but not significantly lower UF volume
with bicPDF. This is in accordance with results from pre-
vious studies with biocompatible lactate-buffered (20),
purely bicarbonate-buffered (35), and mixed lactate-
and bicarbonate-buffered PDF (36), suggesting benefi-
cial effects not only on the peritoneal membrane but also
on RRF. Due to the parallel increase in diuresis and de-
crease in UF, total fluid elimination was comparable at
the end of each study phase. In addition, body weight
did not differ at the end of either study phase (74.9 ±
15.9 kg with bicPDF vs 75.0 ± 16.3 kg with SPDF), there-
by excluding differences in fluid balance during the
12-week study periods. However, to draw conclusions,
investigations applying precise methods of assessing the
effect of conventional and new more biocompatible PD
solutions on patients’ fluid status are required (37).
One of the other advantages of purely bicarbonate-
buffered solutions over lactate-buffered solutions is the
capacity to better control metabolic acidosis (10,14,38).
In our study, a significant change in acid–base param-
eters was visible for base excess and pH. Other acid–base
parameters were unchanged but were already within
normal laboratory ranges at baseline, likely due to the
fact that more than 40% of the patients received oral
bicarbonate substitution.
We could not demonstrate a difference in infusion pain
between bicPDF and SPDF in our population and hence
could not confirm the reduction in infusion pain previ-
ously demonstrated for other biocompatible fluids with
a (near) neutral pH and low GDP content (12,14). How-
ever, the frequency of pain reported by our study popu-
lation was remarkably low, probably due to the fact that
the patients in our study were not selected for the pres-
ence of severe infusion pain as in other studies of this
subject (12,14).
In conclusion, the use of a purely bicarbonate-buff-
ered PD solution proved to be advantageous for PD pa-
tients with increased effluent CA125 concentration. This
suggests better preservation of the mesothelial layer. A
decrease in HA indicates a decrease in peritoneal inflam-
mation. A better preservation of residual renal function
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might have a possible benefit for patient survival. Of
note, we also observed small increases in TNF-a  and
TGF-b 1 with bicPDF, which seemed to contradict our re-
sult with HA. However, these latter results should be in-
terpreted with caution because the levels obtained with
bicPDF were comparable to the levels at baseline and
because the levels were far below those in other studies
with biocompatible peritoneal dialysis fluids. The long-
term benefit of treatment with purely bicarbonate-buff-
ered solution should be proven in a well-designed
randomized long-term study.
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